Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Condition: Mesothelioma, Malignant Interventions: Drug: Nivolumab; Drug: Ramucirumab Sponsors: Arkadiusz Z. Dudek, MD; HealthPartners Institute Regions Cancer Care Center; Eli Lilly and Company; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials